دورية أكاديمية
أعرض في EDS

Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali.

التفاصيل البيبلوغرافية
العنوان: Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali.
المؤلفون: Dicko A; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine Pharmacy and Dentistry, University of Bamako, PO Box 1805 Bamako, Mali. adicko@mrtcbko.org, Sagara I, Djimdé AA, Touré SO, Traore M, Dama S, Diallo AI, Barry A, Dicko M, Coulibaly OM, Rogier C, de Sousa A, Doumbo OK
المصدر: Malaria journal [Malar J] 2010 Jan 10; Vol. 9, pp. 9. Date of Electronic Publication: 2010 Jan 10.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101139802 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2875 (Electronic) Linking ISSN: 14752875 NLM ISO Abbreviation: Malar J Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2002-
مواضيع طبية MeSH: Antimalarials/*pharmacology , Antimalarials/*therapeutic use , Malaria/*drug therapy , Plasmodium/*drug effects , Plasmodium/*genetics , Pyrimethamine/*pharmacology , Pyrimethamine/*therapeutic use , Sulfadoxine/*pharmacology , Sulfadoxine/*therapeutic use, Child, Preschool ; Cross-Sectional Studies ; DNA Mutational Analysis ; DNA, Protozoan/genetics ; Drug Combinations ; Humans ; Infant ; Infant, Newborn ; Male ; Mali ; Point Mutation ; Polymerase Chain Reaction/methods ; Protozoan Proteins/genetics ; Treatment Failure
مستخلص: Background: Intermittent preventive treatment in infants (IPTi) with sulphadoxine-pyrimethamine (SP) given during routine vaccinations is efficacious in preventing malaria disease and shows no interaction with the vaccines. However, there is a fear that IPTi may result in a rapid increase of parasite resistance to SP.
Methods: To evaluate the impact of IPTi on SP-resistance point mutations, the 22 health sub-districts in the district of Kolokani, Mali, were randomized in a 1:1 ratio and starting in December 2006, IPTi with SP was implemented in 11 health sub-districts (intervention zone), while the other 11 health sub-districts served as the control (non-intervention zone). Blood smears and blood dots on filter paper were obtained from children aged 0-5 years, randomly selected in each of heath sub-districts during two cross-sectional surveys. The first survey was conducted in May 2007 before the start of the transmission season to collect baseline prevalence of the molecular markers of resistance to SP and the second in December 2007 after the end of the transmission season and one year after implementation of IPTi. A total of 427 and 923 randomly selected blood samples from the first and second surveys respectively were analysed by PCR for dhfr and dhps mutations.
Results: Each of the three dhfr mutations at codons 51, 59 and 108 was present in 35% and 57% of the samples during the two surveys with no significant differences between the two zones. Dhps mutations at codons 437 and 540 were present respectively in about 20% and 1% of the children during the two surveys in both zones at similar proportion. The prevalence of quadruple mutants (triple dhfr-mutants + dhps-437G) associated with in-vivo resistance to SP in Mali after one year implementation of IPTi was also similar between the two zones (11.6% versus 11.2%, p = 0.90) and to those obtained at baseline survey (10.3% versus 8.1%).
Conclusion: This study shows no increase in the frequency of molecular markers of SP resistance in areas where IPTi with SP was implemented for one year.
References: Malar J. 2009 Feb 26;8:34. (PMID: 19245687)
Acta Trop. 2005 Sep;95(3):172-82. (PMID: 16018959)
J Infect Dis. 2008 Nov 15;198(10):1545-9. (PMID: 18834303)
Acta Trop. 2006 Aug;99(1):106-11. (PMID: 16905111)
J Infect Dis. 2006 Aug 1;194(3):276-85. (PMID: 16826474)
Curr Opin Infect Dis. 2007 Dec;20(6):613-20. (PMID: 17975412)
Am J Trop Med Hyg. 2007 Feb;76(2):237-44. (PMID: 17297030)
Am J Trop Med Hyg. 2008 Mar;78(3):455-61. (PMID: 18337343)
Am J Trop Med Hyg. 1995 Jun;52(6):565-8. (PMID: 7611566)
Lancet. 2009 Oct 31;374(9700):1533-42. (PMID: 19765816)
J Infect Dis. 2000 Sep;182(3):993-6. (PMID: 10950805)
Am J Trop Med Hyg. 2006 Jun;74(6):953-9. (PMID: 16760503)
J Infect Dis. 2008 Jun 15;197(12):1737-42. (PMID: 18419347)
Malar J. 2008 Jul 08;7:123. (PMID: 18611271)
J Infect Dis. 2006 Aug 1;194(3):269-72. (PMID: 16826472)
J Infect Dis. 2005 Dec 1;192(11):1962-5. (PMID: 16267768)
Lancet. 2006 Feb 25;367(9511):659-67. (PMID: 16503464)
BMJ. 2005 Oct 1;331(7519):727-33. (PMID: 16195288)
Lancet. 2008 Oct 18;372(9647):1383-4. (PMID: 18940461)
Trop Med Int Health. 2005 Sep;10(9):901-8. (PMID: 16135198)
Malar J. 2008 Jul 01;7:115. (PMID: 18590577)
Am J Trop Med Hyg. 2006 Jul;75(1):162-5. (PMID: 16837725)
J Infect Dis. 2007 Dec 1;196(11):1595-602. (PMID: 18008242)
N Engl J Med. 2001 Jan 25;344(4):257-63. (PMID: 11172152)
PLoS One. 2007 Jan 03;2(1):e139. (PMID: 17206274)
Lancet. 2001 May 12;357(9267):1471-7. (PMID: 11377597)
Antimicrob Agents Chemother. 2007 Sep;51(9):3273-81. (PMID: 17638703)
Malar J. 2007 Jan 22;6:9. (PMID: 17241476)
Clin Infect Dis. 2007 Jul 1;45(1):16-25. (PMID: 17554695)
Am J Trop Med Hyg. 2007 Apr;76(4):608-13. (PMID: 17426157)
PLoS Med. 2006 May;3(5):e141. (PMID: 16573365)
المشرفين على المادة: 0 (Antimalarials)
0 (DNA, Protozoan)
0 (Drug Combinations)
0 (Protozoan Proteins)
37338-39-9 (fanasil, pyrimethamine drug combination)
88463U4SM5 (Sulfadoxine)
Z3614QOX8W (Pyrimethamine)
تواريخ الأحداث: Date Created: 20100113 Date Completed: 20100312 Latest Revision: 20211020
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC2820043
DOI: 10.1186/1475-2875-9-9
PMID: 20064223
قاعدة البيانات: MEDLINE
الوصف
تدمد:1475-2875
DOI:10.1186/1475-2875-9-9